1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-ol | 326488-07-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-ol
• 英文别名: 2-(4-methoxybenzyl)-5-methyl-2H-pyrazol-3-ol
• CAS: 326488-07-7
• 化学式: C₁₂H₁₄N₂O₂
• 分子量: 218.255
• InChiKey: PFPCGPJEZRUCPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.95
• 重原子数：
  16.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  47.28
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-ol 、 苯甲酰氯 在 三乙胺 作用下， 以 氯仿 为溶剂， 反应 0.08h， 以84%的产率得到1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-yl benzoate
  参考文献：
  名称：

  Structure–activity relationship and improved hydrolytic stability of pyrazole derivatives that are allosteric inhibitors of West Nile Virus NS2B-NS3 proteinase

  摘要：

  West Nile Virus (WNV) is a potentially deadly mosquito-borne flavivirus which has spread rapidly throughout the world. Currently there is no effective vaccine against flaviviral infections. We previously reported the identification of pyrazole ester derivatives as allosteric inhibitors of WNV NS2B-NS3 proteinase. These compounds degrade rapidly in pH 8 buffer with a half life of 1-2 h. We now report the design, synthesis and in vitro evaluation of pyrazole derivatives that are inhibitors of WNV NS2B-NS3 proteinase with greatly improved stability in the assay medium. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.150
• 作为产物：
  描述：

  1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-yl 2,6-difluorobenzoate 以 二甲基亚砜 为溶剂， 生成 1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-ol
  参考文献：
  名称：

  Structure–activity relationship and improved hydrolytic stability of pyrazole derivatives that are allosteric inhibitors of West Nile Virus NS2B-NS3 proteinase

  摘要：

  West Nile Virus (WNV) is a potentially deadly mosquito-borne flavivirus which has spread rapidly throughout the world. Currently there is no effective vaccine against flaviviral infections. We previously reported the identification of pyrazole ester derivatives as allosteric inhibitors of WNV NS2B-NS3 proteinase. These compounds degrade rapidly in pH 8 buffer with a half life of 1-2 h. We now report the design, synthesis and in vitro evaluation of pyrazole derivatives that are inhibitors of WNV NS2B-NS3 proteinase with greatly improved stability in the assay medium. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.150

文献信息

• Anti-HIV pyrazole derivatives
  申请人：——

  公开号：US20030018197A1

  公开（公告）日：2003-01-23

  The present invention comprises novel and known pyrazole derivatives having anti-HIV activity, a process for their manufacture, pharmaceutical compositions and the use of such compounds in medicine. In particular, the compounds of formula I are inhibitors of the human immunodeficiency virus reverse transcriptase enzyme which is involved in viral replication. Consequently the compounds of this invention may be advantageously used as therapeutic agents for HIV infection.

  本发明涵盖具有抗HIV活性的新型和已知吡唑衍生物，其制造方法，药用组合物以及在医学中使用此类化合物。特别是，式I的化合物是人类免疫缺陷病毒逆转录酶酶的抑制剂，该酶参与病毒复制。因此，本发明的这些化合物可优势用作HIV感染的治疗药物。
• PYRAZOLE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1326843A1

  公开（公告）日：2003-07-16
• US6699887B2
  申请人：——

  公开号：US6699887B2

  公开（公告）日：2004-03-02
• US7183296B2
  申请人：——

  公开号：US7183296B2

  公开（公告）日：2007-02-27
• [EN] PYRAZOLE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES<br/>[FR] DERIVES PYRAZOLE DESTINES AU TRAITEMENT DE MALADIES VIRALES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2002030907A1

  公开（公告）日：2002-04-18

  The invention is concerned with novel and known pyrazole derivatives, a process for their manufacture, pharmaceutical compositions and the use of such compounds in medicine. In particular, the compounds of formula (I) are inhibitors of the human immunodeficiency virus reverse transcriptase enzyme which is involved in viral replication. Consequently the compounds of this invention may be advantageously used as therapeutic agents for HIV mediated process. Specifically the invention describes the use of compounds of formula (I) for the treatment of diseases mediated by the human immunodeficiency virus (HIV) or for the preparation of a medicament for such treatment.